Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business – curative cell therapy for solid tumors.
Technologies designed to address major barriers to successful adoptive cell therapy (ACT) in solid tumors.
Our multi-modal product pipeline targets solid tumor cancers with significant unmet medical need.
Dedicated to Patients
An unwavering focus on science guides our mission to deliver transformative T-cell therapies that can go the distance for patients with solid tumors.Learn More
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
Two phase 1 clinical trials recruiting patients at 14 sites across the US; nine sites for LYL797, a ROR-1-targeted chimeric antigen receptor T cell (CAR-T) product candidate, and five sites for LYL845, a tumor infiltrating lymphocyte (TIL) product candidate Cash, cash equivalents and marketableView All News
Join Our Team
At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.
Join our team of ambitious Lyellites who are committed to curing solid tumor cancers through innovation.See Open Positions